Betty Gugliotta married the love of her life, John, after college. They moved to Boulder, Colorado where John worked as an engineer for IBM. Together they raised two beautiful children in the colorful foothills of the Rocky Mountains. 

Betty loved music. She loved to dance with John in the living room of their modern, 1970’s build, ranch-style home, spinning to the sounds of Sinatra. She was, all at the same time, a supermom, awesome wife, and her community’s best friend.

As more and more people turn to cannabis to heal their ailments, a common concern is whether someone should consume cannabis if they are on other prescription medications. It’s an important question – as it’s always important to know how different medications interact with each other – no matter what type of medicine you are taking. In this blog post, we interview a Maine medical professional who is focused on patient education and shares what you need to know when making this consideration.

While more research is necessary, a new study confirms CBD contains neuroprotective potential against degenerative diseases, such as Alzheimer’s and Parkinson’s.

Back in 2003, the U.S. Department of Health and Human Services was granted a patent for the neuroprotective capacity of non-psychoactive cannabinoids. You are not reading that incorrectly. An arm of the federal government, which classifies marijuana as an illegal substance with no accepted medical value, has technology rights to CBD’s ability to protect the brain.

The purpose of due diligence is to reduce risk when entering into an agreement or contract with another party. While it may seem like a pain, the due diligence process is a normal and necessary part of any investment or M&A transaction.

However, there are a few prominent challenges cannabis businesses and their prospective investors or partners encounter when going through the process — mostly due to the unique nature of the cannabis industry.

To illuminate some of the specific challenges cannabis operators face, here are five questions that a potential investor or partner could ask as part of the due diligence process: 

Pot stocks have had better days, to say the least. Well, this sentiment can be shared amongst the entire stock market. With several issues currently plaguing stock prices, what in specific is causing marijuana stocks to drop so heavily in value? Well for starters, issues surrounding the Coronavirus have led the entire world market to see the worst declines in value in over ten years.

Dr. Rudroff recently spoke in depth with The Fresh Toast about common misconceptions and barriers to research currently in place when studying medical marijuana or CBD. 

“We need long-term studies! There is a ‘painful’ parallel between medical marijuana and the past and present situation with opioids, where the short-term demonstration of efficacy on chronic pain led to the promotion and broad scale prescription of opioids in the absence of high quality evidence.”  – Dr. Thorsten Rudroff

It’s critically important to make a distinction between FDA-approved synthetic cannabinoid medications and street synthetic cannabinoids that are used recreationally.

Cannabis produces a wide range of physical and cognitive changes by interacting with receptors designed for our own internal cannabinoids, which are called “endocannabinoids.” These effects are the product of many chemical compounds in cannabis, such as terpenes, flavonoids, and, as this article will focus on, cannabinoids like THC (tetrahydrocannabinol).

Strong cash positions and the ability to negotiate with suppliers will be key for cannabis companies looking to withstand any operational disruption caused by COVID-19, according to one leading cannabis analyst.

Eight Capital’s Graeme Kreindler wrote in a report Monday that the rise of coronavirus cases globally is likely to see the cannabis sector in North America face the supply chain pressures that other industries are already facing – mainly sourcing items from China and finding protective gear.

Pot stocks were hammered in 2019. Nearly every company lost at least 50% of its value. Cannabis demand, on the other hand, continues to climb. This disconnect provides patient investors a clear path to profit.

As with any early-stage market, investors scrambled at the chance to inject pent-up capital into cannabis companies. In 2018, many pot stocks rose by more than 1,000%. By 2019, the hype bubble had popped, sending short-term investors to the sidelines.

Pot stocks were overvalued in 2018, but there’s an argument that the pendulum has swung too far the other way. It doesn’t take a mathematician to realize that many cannabis producers are trading at bargain valuations.

According to new research, the average age when teens first try drugs, such as cocaine, heroin, and marijuana, has risen since 2004.

The advent of marijuana reform across North America caused politicians and parents alike to worry about teenagers having easy access to cannabis. But in places where marijuana has become legal for adult-use, adolescents are smoking weed less, not more. This is true in Canada, where marijuana is more recently legal, as well as a city like Denver, an early site of recreational marijuana.